Therapeutic drug in COVID arsenal

This news has been read 60658 times!

KUWAIT CITY, July 13: The Ministry of Health has expanded its options in adopting COVID-19 vaccines and drugs. It has received the first shipment of the new drug Sotrovimab from the GSK Company, after clinical studies proved its ability to reduce hospitalizations and deaths related to COVID-19 infection by 85 percent for mild and medium cases. Assistant Undersecretary for Medicine and Medical Equipment Affairs at Ministry of Health Dr. Abdullah Al-Bader said, “With great interest, our scientific and regulatory teams are looking forward to new, effective and safe treatments and vaccines to confront the pandemic.

The ministry is working with the GSK Company to implement treatment protocols that help doctors in identifying patients at risk and ensuring their access to Sotrovimab.” Meanwhile, the Vice President and General Manager of GSK Company – Gulf Dr. Jezem Akalin praised the “close cooperation between Kuwait’s Ministry of Health and our company in order to explore options for expediting access to this new and promising drug in Kuwait”. She expressed her satisfaction with the rapid response of the officials of Kuwait’s Ministry of Health in evaluating the treatment”. Within 24 hours, the ministry took the decision to expedite the review and put in place an agreement to secure quick access to the medicine for the patients in Kuwait.

In addition, the Technical Committee for COVID-19 Vaccines authorized the change of the vaccine platform for the second dose in case there are people who have contraindications to taking the same vaccine type of the first dose, and pregnant women who received the first dose before pregnancy and whose condition requires changing the type of vaccine for the second dose. The committee also decided to allow vaccination certificates for individuals who completed vaccination abroad from different vaccination facilities, provided that those vaccines are approved in Kuwait. Chairman of the Supreme Advisory Committee for COVID-19 Professor Dr. Khaled Al-Jarallah praised the decision of the COVID- 19 Vaccines Technical Committee to adopt the option of diversifying some vaccine platforms for certain segments and cases. On his Twitter account, he affirmed that the diversity of some platforms has become “acceptable and desirable following the frequency of studies that indicate the doubled immune activity, which was previously foreseen”. As Aug 1 is fast approaching, many citizens are inquiring about travel procedures, particularly those concerning the 12 to 15-year-olds due to the possibility of extending the period of application for travel requirements for this group, thus, they can travel even if they are not vaccinated against coronavirus, reports Al- Rai daily quoting sources.By Marwa Bahrawi Al-Seyassah, Arab Times Staff and Agencies

This news has been read 60658 times!

Related Articles

Back to top button

Advt Blocker Detected

Kindly disable the Ad blocker

Verified by MonsterInsights